Breast Neoplasms clinical trials

The registry lists 14,825 studies for Breast Neoplasms across more than 10 countries. 3,319 are recruiting or about to start. 12,529 of them are mainly about Breast Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 9 narrower conditions too, such as Triple Negative Breast Neoplasms: 15,797 studies, 3,664 open.

ClinicalTrials.gov finds 16,998 studies for Breast Neoplasms. How that becomes 14,819 here

This page counts the studies the registry files under Breast Neoplasms, and those it files under no condition that list Breast Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

16,998Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−971Filed under a narrower condition, counted on its own pageTriple Negative Breast Neoplasms 732 · Carcinoma, Intraductal, Noninfiltrating 86 · Hereditary Breast and Ovarian Cancer Syndrome 38 · Breast Carcinoma In Situ 27 · Inflammatory Breast Neoplasms 22 · Carcinoma, Lobular 22 · 3 more
−397List Breast Neoplasms as a condition, but the registry did not file them under itMost often written as “Breast Cancer Female” (54), “Breast Cancer Lymphedema” (25), and “Anatomic Stage III Breast Cancer AJCC v8” (20). The registry filed them under other conditions only, most often Breast Cancer Lymphedema (63) and Neoplasms (29).
−811Match it another way570 name it in the title, 49 in a keyword, and 192 by a synonym or other text the search reads.
14,819The count on this page1,285 of them list Breast Neoplasms in their own words; the registry filed them under no condition.

Status

Completed: 6,985
Recruiting: 2,400
Status unknown: 1,614
Terminated: 1,247
Active, not recruiting: 1,118
Not yet recruiting: 808

Phase

Phase 2: 3,982
Phase 1: 2,030
Phase 3: 1,418
Phase 4: 306
Early Phase 1: 196

Where

United States: 6,163
China: 1,927
France: 1,208
Canada: 906
Spain: 905
Italy: 886

Who runs them

National Cancer Institute (NCI) (298) · Fudan University (260) · Memorial Sloan Kettering Cancer Center (253) · M.D. Anderson Cancer Center (230) · AstraZeneca (194) · Hoffmann-La Roche (179) · Novartis Pharmaceuticals (178) · Pfizer (161)

What is being tested here

Drugs under test in Breast Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Trastuzumab	34	54	324
Trastuzumab rezetecan	33	6	36
Paclitaxel	32	62	348
Pyrotinib	30	11	65
Capecitabine	27	52	220
Trastuzumab deruxtecan	26	11	51
Dalpiciclib	26	3	39
Letrozole	20	44	150
Pembrolizumab	20	7	78
Abemaciclib	20	10	48

Drug classes tested here Immune checkpoint inhibitors 83 open · Tyrosine kinase inhibitors (TKIs) 75 open · Antibody-drug conjugates (ADCs) 70 open · Antimitotic agents 52 open · Aromatase inhibitors 43 open

Coming up

424phase 3 studies under way

1,248studies finish main data collection within a year71 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation · Phase 3 · M.D. Anderson Cancer Center
Nov 2026A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · Phase 3 · Hoffmann-La Roche
Nov 2026Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients · Phase 3 · Mayo Clinic
Nov 2026Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia · Phase 3 · Northwestern University
Nov 2026A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer · Phase 3 · InventisBio Co., Ltd
Nov 2026A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy · Phase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Dec 2026Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Dec 2026Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) · Phase 3 · Gilead Sciences
Dec 2026Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer · Phase 3 · Universitaire Ziekenhuizen KU Leuven
Dec 2026Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer · Phase 3 · ETOP IBCSG Partners Foundation

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger. 103 (4%) take children under 18. 1,272 (53%) are for women only and 3 (<1%) for men only; 214 (9%) take healthy volunteers.

Recruiting studies that take each age, of 2,400
Age	Women	Men
10	95 (4%)	46 (2%)
18	2,065 (86%)	1,052 (44%)
30	2,238 (93%)	1,096 (46%)
40	2,290 (95%)	1,104 (46%)
50	2,317 (97%)	1,108 (46%)
65	2,312 (96%)	1,108 (46%)
75	2,067 (86%)	1,076 (45%)
85	1,712 (71%)	973 (41%)

Across all 14,825 studies, recruiting or not: 23% stop at 75 or younger and 7% at 65; 6% take children; 64% are for women only and <1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Breast Neoplasms studies take

Of 1,302 phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	44 mo25–66 · 759 studies	39 mo22–56 · 388 studies	48 mo28–77 · 371 studies
Phase 1/2	61 mo45–88 · 327 studies	59 mo44–75 · 161 studies	64 mo45–95 · 166 studies
Phase 2	51 mo30–82 · 1,302 studies	34 mo22–53 · 232 studies	56 mo34–87 · 1,070 studies
Phase 2/3	57 mo32–88 · 56 studies	—	57 mo31–91 · 43 studies
Phase 3	59 mo36–96 · 600 studies	40 mo28–63 · 272 studies	79 mo50–127 · 328 studies
Phase 4	42 mo20–64 · 130 studies	—	46 mo20–64 · 110 studies
Interventional, no phase	33 mo15–66 · 2,771 studies	24 mo10–74 · 110 studies	33 mo16–66 · 2,661 studies
Observational	55 mo25–126 · 1,380 studies	43 mo26–70 · 189 studies	58 mo25–139 · 1,191 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out